These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 23459699

  • 1. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, Essioux L, Klause U.
    Rheumatology (Oxford); 2013 Jul; 52(7):1245-53. PubMed ID: 23459699
    [Abstract] [Full Text] [Related]

  • 2. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 3. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

  • 4. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 5. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [Abstract] [Full Text] [Related]

  • 6. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 7. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ.
    JAMA; 2011 Apr 13; 305(14):1460-8. PubMed ID: 21486979
    [Abstract] [Full Text] [Related]

  • 8. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.
    Rheumatology (Oxford); 2011 Aug 13; 50(8):1445-52. PubMed ID: 21427177
    [Abstract] [Full Text] [Related]

  • 9. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan 13; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
    Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, Kelsall JT, Lehman AJ, Shawi M, Khalil H, Nantel F, Rampakakis E, Sampalis JS, Otawa S.
    Arthritis Care Res (Hoboken); 2014 Aug 13; 66(8):1142-51. PubMed ID: 24470077
    [Abstract] [Full Text] [Related]

  • 11. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan 13; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 12. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec 13; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 13. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.
    Scand J Rheumatol; 2008 Dec 13; 37(1):6-12. PubMed ID: 18189188
    [Abstract] [Full Text] [Related]

  • 14. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC, Larsson L, Truedsson L, Sturfelt G, Saxne T, Geborek P.
    Arthritis Res Ther; 2006 Dec 13; 8(4):R131. PubMed ID: 16869978
    [Abstract] [Full Text] [Related]

  • 15. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.
    De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2003 Apr 13; 48(4):1015-23. PubMed ID: 12687543
    [Abstract] [Full Text] [Related]

  • 16. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K.
    Ann Rheum Dis; 2009 Nov 13; 68(11):1739-45. PubMed ID: 19019895
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec 13; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 18. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 13; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 19. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians.
    Arthritis Rheum; 2009 May 15; 61(5):560-8. PubMed ID: 19405000
    [Abstract] [Full Text] [Related]

  • 20. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec 15; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.